Preparation and characterization of alginate gel core-lipid nanocapsules for co-delivery of hydrophilic and hydrophobic anti-cancer drugs

다국어 초록 (Multilingual Abstract)

Novel alginate gel-core lipid nanocapsules(LNCs) consisting of hydrogel islets in an oil filled matrixand surrounded by a polymeric shell were prepared by hothomogenization and double emulsion method, for codeliveryof both hydrophilic (gemcitabine) and hydrophobic(paclitaxel) anticancer drugs. This system was preparedusing a relatively simple and organic solvent-free methodusing only excipients that are approved by the FDA. Theliquid oil matrix allowed the solubilization and encapsulationof hydrophobic drugs such as paclitaxel, whereasalginate hydrogel islets encapsulated hydrophilic drugssuch as gemcitabine. Alginate gel-core LNCs were characterizedwith respect to particle size, polydispersity index(PDI), morphology, encapsulation efficiency, and in vitrorelease. Dual drug-loaded alginate gel-core LNCs had aparticle size of 171.8 ± 4.1 nm and PDI of 0.201 ± 0.005,respectively, and showed core–shell type spherical morphologywith a smooth surface. In addition, alginate gelcore-LNCs underwent sustained release of both drugs.
These results suggest that alginate gel core-LNCs may beused for co-delivery of hydrophilic (gemcitabine) andhydrophobic (paclitaxel) anticancer drugs.

참고문헌 (Reference)

1 Chabner BA, "Timeline: chemotherapy and the war on cancer" 5 (5): 65-72, 2005

2 Heurtault B, "The influence of lipid nanocapsule composition on their size distribution" 18 (18): 55-61, 2003

3 Frey SL, "Temperature dependence of poloxamer insertion into and squeeze-out from lipid monolayers" 23 (23): 2631-2637, 2007

4 Sanna V, "Targeted therapy using nanotechnology:focus on cancer" 9 : 467-483, 2014

5 Owens DE 3rd, "Opsonization, biodistribution and pharmacokinetics of polymeric nanoparticles" 307 (307): 93-102, 2006

6 Perrier T, "OPA quantification of amino groups at the surface of lipidic nanocapsules (LNCs) for ligand coupling improvement" 419 (419): 266-270, 2011

7 Liboiron BD, "Nanoscale particulate systems for multidrug delivery: towards improved combination chemotherapy" 5 (5): 149-171, 2014

8 Hu CM, "Nanoparticle-assisted combination therapies for effective cancer treatment" 1 (1): 323-334, 2010

9 Anton N, "Nano-emulsions and nanocapsules by the PIT method: an investigation on the role of the temperature cycling on the emulsion phase inversion" 344 (344): 44-52, 2007

10 Huynh NT, "Lipid nanocapsules: a new platform for nanomedicine" 379 (379): 201-209, 2009

11 Hirsja¨rvi S, "Influence of size, surface coating and fine chemical composition on the in vitro reactivity and in vivo biodistribution of lipid nanocapsules versus lipid nanoemulsions in cancer models" 9 (9): 375-387, 2013

12 Vonarbourg A, "Evaluation of pegylated lipid nanocapsules versus complement system activation and macrophage uptake" 78 (78): 620-628, 2006

13 Be´duneau A, "Design of targeted lipid nanocapsules by conjugation of whole antibodies and antibody Fab’ fragments" 28 (28): 4978-4990, 2007

14 Al-Lazikani B, "Combinatorial drug therapy for cancer in the post-genomic era" 30 (30): 679-692, 2012

15 Pinto AC, "Combination chemotherapy in cancer: principles, evaluation and drug delivery strategies, current cancer treatment—novel beyond conventional approaches"

16 Heurtault B, "A novel phase inversion-based process for the preparation of lipid nanocarriers" 19 (19): 875-880, 2002